Reading the tape
NASDAQ: ORGO
Organogenesis Holdings Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$329.32M
52w High
$7.08
52w Low
$2.21
P/E
8.77
Volume
2.10M
Outstanding Shares
128.64M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -51.88%Revenue (TTM): 16.99%FCF (TTM): -685.73%P/E: 11th pct
What changed
The stock fell 51.88% over the last year. Revenue grew 16.99% over the trailing twelve months. Operating margin moved from -0.27% to 8.27%. Free cash flow declined 685.73% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 11th percentile of their historical P/E range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 8.27%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
CEOGary S. Gillheeney
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees869
IPO dateJan 5, 2017
Valuation
Forward P/E—
EV/EBITDA8.35
Enterprise value$695.67M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth78.13%
Gross margin74.37%▼3.18%vs FY2024
Operating margin8.27%▲3855.03%vs FY2024
ROE8.53%▲3719.30%vs FY2024
Analyst consensus
RatingBuy
Target price$9.00▲251.56%
4
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.29 · Revenue est $43.26M
View